Adamis Pharmaceuticals, a commercial-stage biopharmaceutical company, changed its name to DMK Pharmaceuticals Corp., a move designed to better reflect the company’s new strategic focus on advancing small molecules for the treatment of substance use disorders.  Eboo Versi, CEO of Adamis said, “The new DMK Pharmaceuticals is committed to developing groundbreaking and innovative therapies to establish itself as a leader in the treatment of substance abuse including opioid and alcohol use disorde...